[{"address1": "Hegenheimermattweg 91", "city": "Allschwil", "zip": "4123", "country": "Switzerland", "phone": "41 58 844 10 10", "website": "https://www.idorsia.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant) for the treatment of adult patients with insomnia. The company has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and commercialize PIVLAZ. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Jean-Paul  Clozel M.D.", "age": 68, "title": "CEO & Chairman of the Board", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 1017842, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andre C. Muller", "age": 60, "title": "Executive VP & CFO", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martine  Clozel", "age": 68, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1955, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Guy  Braunstein M.D.", "age": 67, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alberto  Gimona M.D.", "age": 63, "title": "Executive VP & Head of Global Clinical Development", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew C. Weiss", "age": 55, "title": "Senior VP and Head of Investor Relations & Corporate Communications", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Julien  Gander L.L.M.", "age": 44, "title": "Senior VP, Group General Counsel & Company Secretary", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Khatuntsev", "age": 45, "title": "Senior VP & Head of Global Human Resources", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Olivier  Lambert", "age": 57, "title": "Senior VP & Head of Technical Operations", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Markus A. Riederer", "age": 61, "title": "Senior VP & Head of Drug Discovery Biology", "yearBorn": 1962, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 2, "compensationRisk": 4, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.15, "open": 2.15, "dayLow": 2.25, "dayHigh": 2.3, "regularMarketPreviousClose": 2.15, "regularMarketOpen": 2.15, "regularMarketDayLow": 2.25, "regularMarketDayHigh": 2.3, "beta": 1.178, "trailingPE": 12.95, "volume": 14000, "regularMarketVolume": 14000, "averageVolume": 231, "averageVolume10days": 1000, "averageDailyVolume10Day": 1000, "marketCap": 466404608, "fiftyTwoWeekLow": 1.4, "fiftyTwoWeekHigh": 5.56, "priceToSalesTrailing12Months": 3.648432, "fiftyDayAverage": 2.407, "twoHundredDayAverage": 2.227635, "currency": "USD", "enterpriseValue": 1483637248, "profitMargins": 0.22418, "floatShares": 102981004, "sharesOutstanding": 180079008, "heldPercentInsiders": 0.36078, "heldPercentInstitutions": 0.22448999, "bookValue": -5.79, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": 28659000, "trailingEps": 0.2, "enterpriseToRevenue": 11.606, "enterpriseToEbitda": -4.38, "exchange": "OEM", "quoteType": "EQUITY", "symbol": "IDRSF", "underlyingSymbol": "IDRSF", "shortName": "IDORSIA LTD", "longName": "Idorsia Ltd", "firstTradeDateEpochUtc": 1500298200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "7567121c-a1e8-315a-862e-2c66fcc9c342", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.59, "recommendationKey": "none", "totalCash": 248004000, "totalCashPerShare": 1.377, "ebitda": -338747008, "totalDebt": 1265337984, "quickRatio": 0.676, "currentRatio": 0.922, "totalRevenue": 127837000, "revenuePerShare": 0.714, "returnOnAssets": -0.37333, "freeCashflow": -109906496, "operatingCashflow": -402728000, "revenueGrowth": -0.454, "grossMargins": -0.55805, "ebitdaMargins": -2.64984, "operatingMargins": -5.81617, "financialCurrency": "CHF", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]